Irene van der Heijden has a type of cancer that is incurable, inoperable and notoriously resistant to chemotherapy — low-grade serous ovarian cancer with carcinomatosis of the peritoneum, a thin...

City of Hope scientists will showcase research at the AACR Virtual Annual Meeting II that could one day lead to real-time diagnostic imaging and leading-edge genomic profiling that improve health...

“People thought City of Hope was a ship!”   It’s hard to believe, but there was a time when the sprawling, globally recognized City of Hope we all recognize today...

“We’re expanding the paradigm of how to do clinical studies.”   Kimlin Tam Ashing, Ph.D., is speaking excitedly about a new clinical trial that’s breaking some old norms in order to...

In a clinical trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer — findings...

Enormous additions to our knowledge of human biology at the molecular and genetic level have opened the door to a potential “golden age” of cancer treatment — where every tumor...

In a collaboration with Caltech, Peter P. Lee, M.D., chair of City of Hope’s Department of Immuno-Oncology and co-leader of the Cancer Immunotherapeutics Program, and members of his lab are developing a...

For Leanne Burnham, Ph.D., a postdoctoral fellow in City of Hope's  Division  of  Health  Equities, the search for a more effective prostate cancer treatment is deeply personal. As an African American...

City of Hope was founded by donors and volunteers, creating hope and healing for millions of people around the globe. That enduring legacy of philanthropy continues today — driving our...

A Phase 2 clinical trial at City of Hope has shown that monotherapy with sotorasib results in anti-tumor activity and a favorable benefit-risk profile among heavily pretreated patients with advanced colorectal...